Treatment Development for Smoking Cessation and Engagement in HIV/TB

Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Aged 18 or older

• Willing and able to provide written informed consent

• Living with HIV, confirmed via medical record, and on antiretroviral therapy (ART) AND/OR within 1 month of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture

⁃ (5) Daily smoker operationalized as \> 5 cigarettes per day, (6) Motivation (\> 5/10) to quit smoking or \> 24 hour quit past yr

Locations
Other Locations
South Africa
University of Cape Town
RECRUITING
Rondebosch
Contact Information
Primary
Conall O'Cleirigh, PhD
cocleirigh@mgh.harvard.edu
617-643-0385
Backup
Brianna A Estrada, BS
bestrada@mgh.harvard.edu
617-643-2147
Time Frame
Start Date: 2024-03-12
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 86
Treatments
Experimental: QUIT-AD
An six-session adapted cognitive-behavioral intervention for smoking cessation and treatment adherence. Intervention content will include psychoeducation related to cognitive-behavioral therapy, smoking, TB, and HIV; behavioral activation; distress tolerance; and relapse prevention.
Active_comparator: Enhanced Treatment as Usual (ETAU)
After randomization, participants in the ETAU condition will receive one session of psychoeducation on the HIV- and TB-related health benefits of smoking cessation.
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: Boston University, University of Cape Town

This content was sourced from clinicaltrials.gov